XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can’t continue continuous infusion therapy
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: 1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous injection on day 1.) Primary outcome(s): FOLFOX(+bevacizumab) from PFS Study Design: Single arm Non-randomized
创建时间：
2010-07-15
